BridgeBio Oncology <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Poster Presentations on Novel KRAS Inhibitors at 2025 AACR-NCI-EORTC Conference
BridgeBio Oncology Therapeutics Inc. $(BBOT)$ has announced upcoming poster presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scheduled for October 22-26, 2025, in Boston, Massachusetts. The company will present data on BBO-11818, an orally bioavailable, highly potent and selective non-covalent pan-KRAS$(ON)$ and (OFF) inhibitor, which has demonstrated robust anti-tumor activity in KRAS-mutant preclinical models. Additionally, BBOT will present findings on BBO-10203, described as a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction, which inhibits tumor growth alone and in combination with KRAS inhibitors in KRAS mutant models without inducing hyperglycemia. The results will be presented during scheduled poster sessions at the conference.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bridgebio Oncology Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544680-en) on October 13, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。